RecruitingPhase 2NCT03649880

Feasibility of FMISO in Brain Tumors

Feasibility of [¹⁸F]-Fluoromisonidazole (FMISO) in Assessment of Malignant Brain Tumors

Sponsor

OHSU Knight Cancer Institute

Enrollment

50 participants

Start Date

Jun 1, 2019

Study Type

INTERVENTIONAL

Conditions

Malignant Brain Neoplasm

Summary

This phase II trial studies how well ¹⁸F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors. FMISO provides information about the oxygen levels in a tumor, which may affect how the tumor behaves. PET/MRI imaging produces images of the brain and how the body functions. FMISO PET/MRI may help investigators see how much oxygen is getting in the brain tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing whether a special PET scan using a tracer called FMISO can detect areas of low oxygen (hypoxia) inside brain tumors, which may help doctors plan more targeted and effective treatment. **You may be eligible if...** - You are 18 years old or older - You have a known or suspected brain tumor (malignant or benign) - You or your legal representative can give written informed consent **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have severe kidney problems that prevent clearance of the imaging agent - You are claustrophobic or unable to tolerate PET/MRI scanning - You are unable to give consent and have no legal representative available Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.